Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Alzheimer's Disease Clinical Trial

Official title:

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00051909
• Other study ID #: 6764
• Secondary ID: H6N-MC-LEAM
• Status: Completed
• Phase: Phase 2
• First received: January 17, 2003
• Last updated: July 18, 2006
• Start date: November 2002
• Est. completion date: June 2003

Study information

• Verified date: July 2006
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: June 2003
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Must have a clinical diagnosis of Alzheimer's Disease

• Must be at least 50 years of age

• Must fluently read and speak English

• Must have a reliable caregiver

Exclusion Criteria:

• Has serious health problems other than Alzheimer's Disease

• Cannot swallow whole pills

• Has had a menstrual period in the last two years

• Takes insulin for diabetes

• Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• LY451395

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States,